Business Segments Monte Rosa Therapeutics, Inc.
Stocks
GLUE
US61225M1027
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.71 USD | +0.64% |
|
-30.73% | +0.19% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
Biological Products | |||||||
Biotechnology (Startups) | - | - | - | 7.56Cr | 12Cr | ||
Total Assets | 37Cr | 34Cr | 30Cr | 44Cr | 45Cr | ||
Interest Expense | - | - | - | - | - | ||
Income Tax Expense | - | - | 3L | 25.7L | -10.97L | ||
CAPEX | -97.32L | -1.29Cr | -1.9Cr | -39.88L | -47L | ||
EBT | -7.4Cr | -11Cr | -14Cr | -7.01Cr | -3.97Cr | ||
D&A | 21.32L | 37.45L | 62.22L | 1.02Cr | 1.09Cr | ||
Operating Income | -7.29Cr | -11Cr | -14Cr | -8.11Cr | -5.42Cr | ||
Net Income | -7.4Cr | -11Cr | -14Cr | -7.27Cr | -3.86Cr |
Geographical Revenue Distribution History
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
United States | - | - | - | 7.56Cr | 12Cr | ||
Total Assets | 37Cr | 34Cr | 30Cr | 44Cr | 45Cr | ||
Interest Expense | - | - | - | - | - | ||
Income Tax Expense | - | - | 3L | 25.7L | -10.97L | ||
D&A | 21.32L | 37.45L | 62.22L | 1.02Cr | 1.09Cr | ||
CAPEX | -97.32L | -1.29Cr | -1.9Cr | -39.88L | -47L | ||
Net Income | -7.4Cr | -11Cr | -14Cr | -7.27Cr | -3.86Cr | ||
EBT | -7.4Cr | -11Cr | -14Cr | -7.01Cr | -3.97Cr | ||
Operating Income | -7.29Cr | -11Cr | -14Cr | -8.11Cr | -5.42Cr |
- Stock Market
- Stocks
- GLUE Stock
- Financials Monte Rosa Therapeutics, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
